yeting hu

Dr. yeting hu

Zhejiang University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cancer Letters
Verified
Journal Article
Closed access
QXQian Xiao
Qian Xiao
WLWei Lu
Wei Lu
XKXiangxing Kong
Xiangxing Kong
YSYang Shao
Yang Shao
YHyeting hu
yeting hu
KDKefeng Ding
Kefeng Ding

11 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RZRui Zhang
Rui Zhang
CFCui Feng
Cui Feng
DLDandan Luo
Dandan Luo
RZRuibo Zhao
Ruibo Zhao
PKPerumal Ramesh Kannan
Perumal Ramesh Kannan
XKXiangdong Kong
Xiangdong Kong
Rotavirus is one of the main pathogens that causes severe diarrhea in children under the age of 5, primarily infecting the enterocytes of the small intestine. Currently, there are no specific drugs available for oral rehydration and antiviral therapy targeting rotavirus. However, metformin hydrochloride, a drug known for its antiviral properties, shows promise as it accumulates in the small intestine and modulates the intestinal microbiota. Therefore, we formulated a hypothesis that metformin hydrochloride could inhibit rotavirus replication in the intestine. To validate the anti-rotavirus effect of metformin hydrochloride, we conducted infection experiments using different models, ranging from in vitro cells and organoids to small intestines in vivo. The findings indicate that a concentration of 0.5 mM metformin hydrochloride significantly inhibits the expression of rotavirus mRNA and protein in Caco-2 cells, small intestinal organoids, and suckling mice models. Rotavirus infections lead to noticeable pathological changes, but treatment with metformin has been observed to mitigate the lesions caused by rotavirus infection in the treated group. Our study establishes that metformin hydrochloride can inhibit rotavirus replication, while also affirming the reliability of organoids as a virus model for in vitro research.

26 December 2025 in Cancer Medicine
Verified
Journal Article
Open access
XGXiaoxu Ge
Xiaoxu Ge
GYGuanli Yang
Guanli Yang
HWHuiming Wu
Huiming Wu
LLLei Liu
Lei Liu
MZMing Zhou
Ming Zhou
JWJian Wang
Jian Wang
Background: Colorectal cancer (CRC) with synchronous peritoneal metastasis (SPM) presents poor prognosis and complex treatment challenges. This study aimed to identify independent prognostic factors and develop nomogram‐based prediction models for overall survival (OS) and progression‐free survival (PFS) in CRC patients with SPM (CRC‐SPM) undergoing cytoreductive surgery (CRS). Methods: We retrospectively analyzed 218 CRC‐SPM treated with CRS between October 2010 and April 2022. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors for OS and PFS. Nomogram models were constructed based on these factors, and their predictive accuracy was assessed using calibration curves, ROC curves, and Decision Curve Analysis (DCA). Results: For OS, independent factors included age > 65 years (HR = 2.464, p = 0.005), N2 stage (HR = 2.720, p = 0.005), > 13 lymph nodes resected (HR = 0.496, p = 0.018), and postoperative chemotherapy ( HR = 0.300, p = 0.020). For PFS, independent factors were age > 65 years ( HR = 1.578, p = 0.040), concurrent liver metastasis ( HR = 1.664, p = 0.016), > 14 PCI score ( HR = 1.630, p = 0.031), and presence of ascites ( HR = 1.706, p = 0.011). Nomogram models for predicting OS and PFS had AUC values of 0.717, 0.759, and 0.773 for OS, and 0.659, 0.689, and 0.790 for PFS at 1, 2, and 3 years, respectively. Conclusion: This study identified key prognostic factors and developed reliable nomogram models for predicting OS and PFS in CRC‐SPM. The findings highlight the importance of postoperative chemotherapy and intraoperative lymph node dissection and suggest focusing on high‐risk factors such as age and N2 stage in clinical practice. The nomogram models provide a valuable tool for personalized prognosis assessment and treatment planning.

15 March 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
JXJiasheng Xu
Jiasheng Xu
YHyeting hu
yeting hu
JZJie Zhao
Jie Zhao
XKXiangxing Kong
Xiangxing Kong
SXSijian Xia
Sijian Xia
KDKefeng Ding
Kefeng Ding

5 May 2026 in Communications Biology
Verified
Journal Article
Open access
KJKunpeng Jia
Kunpeng Jia
YDYuxin Ding
Yuxin Ding
MJMenglei Jin
Menglei Jin
QYQi Yang
Qi Yang
XWXinyu Wang
Xinyu Wang
ZCZhigang Chen
Zhigang Chen
Chemotherapy resistance remains a major challenge in advanced colorectal cancer (CRC), with chemotherapy-induced senescence playing a key role. While cancer cell senescence has been extensively studied, the contribution of stromal components, particularly vascular endothelial cells, remains unclear. Here, we analyze 77 CRC patients undergoing neoadjuvant chemotherapy and find that favorable responders exhibit well-defined vascular lumens, whereas poor responders show an increase in senescent endothelial cells (senEndo), as revealed by single-cell transcriptomics and immunofluorescence. Chemotherapy-induced senescence reduces GPX4 ubiquitylation in senEndo, leading to its accumulation and extracellular vesicle transfer to CRC cells, where it inhibits ferroptosis and promotes chemoresistance. In vitro and in vivo models demonstrate that targeting GPX4 with the ferroptosis activator RSL3 restores chemotherapy sensitivity. These findings identify a novel mechanism of chemoresistance mediated by senEndo-derived GPX4 in extracellular vesicles and highlight the potential of ferroptosis induction, alone or in combination with senolytic agents, to improve 5-Fu/oxaliplatin-based CRC therapies.

10 March 2026 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
YQYucheng Qian
Yucheng Qian
JWJingsun Wei
Jingsun Wei
YBYuan Bian
Yuan Bian
YTYinuo Tan
Yinuo Tan
YFYimin Fang
Yimin Fang
YHyeting hu
yeting hu
Objective: Colorectal cancer (CRC) progression is driven by cancer stem cells (CSCs) that evade treatment through dynamic phenotype modulation. Our previous research identified BEX2 as a significant regulator of CRC malignancy involving the Hedgehog (Hh) pathway. This study aimed to elucidate the influence of BEX2 on CRC stemness and the interaction with the Hh signaling pathway, potentially uncovering innovative therapeutic strategies for combating CRC. Methods: TCGA and GEO data were analyzed to correlate BEX2 expression with clinical outcomes and stemness markers in CRC. Functional assays, including spheroid formation, flow cytometry, extreme limiting dilution assay (ELDA), Transwell, wound healing, and cell viability assay, were performed in DLD1 and HCT116 cell lines. Immunoblotting and qRT-PCR assessed BEX2 expression with in vivo validation in NOD/SCID mice. Results: The findings revealed a negative correlation between BEX2 expression and the levels of stemness-associated genes with a significant association with CRC patient’ prognosis. Overexpression of BEX2 diminished CRC stemness potential, whereas BEX2 knockdown led to a pronounced enhancement of these stem-like characteristics. Further investigation revealed that BEX2 inhibited the Hh pathway. BEX2 interacted with MCL1, promoting ubiquitination and degradation, thereby decreasing MCL1 stability. Low BEX2 expression stabilized MCL1, which enhanced stemness potential. These results suggested BEX2 modulates CRC stemness via MCL1 downregulation. Conclusions: Taken together, the current study findings highlight BEX2 and MCL1 as potential therapeutic targets in CRC with BEX2 emerging as a key regulator of stemness, chemoresistance, and invasiveness. These findings advance our understanding of CRC and pave the way for more effective therapies.